Published: 8 September 2021
Author(s): Luciano Gattinoni, Mattia Busana, Luigi Camporota
Issue: October 2021
Section: Commentary

The coronavirus disease 2019 (COVID-19) causes acute respiratory failure (ARF) altering the pulmonary microvasculature with simultaneous vasoconstriction and thrombosis in ventilated areas, hyperperfusion [1] and neo-angiogenesis in gasless regions [2]. The progressive derangement of the lung vasculature and parenchyma worsens the shunt fraction and deadspace, and consequently hypoxaemia and hypercapnia.

Newsletters

Stay informed on our latest news!